Balancing safety, competition and differentiation in modern target selection

A framework to prioritize therapeutic opportunities in evolving modalities such as targeted protein degradation

Selecting the right therapeutic targets has never been more challenging.

As drug discovery expands beyond traditional small molecules into emerging modalities such as targeted protein degradation (TPD), early-stage decisions carry greater implications for program success.
Teams must evaluate not only scientific promise, but also competitive dynamics, translational feasibility, and potential safety liabilities before committing valuable resources.

In this eBook, Clarivate demonstrates how combining competitive landscape intelligence with mechanism-based safety assessment can help organizations make more confident, evidence-based target prioritization decisions.

Using BTK as a real-world case study, you’ll learn how to assess whether a degrader strategy offers meaningful advantages over existing approaches, while identifying areas where differentiation and long-term value creation are most likely to emerge.

Download the eBook to learn

• How to evaluate emerging therapeutic opportunities using a structured target prioritization framework
• Where pathways such as Accelerated Approval, Priority Review, PRIME, Conditional Marketing Authorisation and Sakigake deliver the greatest value—and the considerations associated with each
• Where unmet opportunities may exist in the rapidly evolving TPD field
• How genetic evidence, pathway biology and translational safety data can help identify potential risks earlier
• What BTK degraders reveal about resistance biology, safety considerations and competitive differentiation
• How to balance innovation, safety and commercial viability when selecting targets for future investment